Evicenter
P&T meetings

Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Regulatory submission
NDA submitted September 2025
Last updated
217 sources

Company-reported prevalence

Juvmo

Overview

FieldValue
DrugJuvmo (tavapadon)
IndicationParkinson's disease
DiseaseParkinson's disease
CompanyAbbVie (worldwide rights, since its acquisition of Cerevel Therapeutics in August 2024); Cerevel Therapeutics (developer until August 2024, under a 2018 license from Pfizer)
Documents searchedAbbVie press release, September 28, 2026 (FDA approval); AbbVie press release, September 26, 2025 (NDA submission); AbbVie press release, December 9, 2024 (TEMPO-2 topline results); AbbVie press release, September 26, 2024 (TEMPO-1 topline results); AbbVie press release, August 1, 2024 (completion of the Cerevel Therapeutics acquisition); AbbVie press release, December 6, 2023 (agreement to acquire Cerevel Therapeutics); AbbVie Form 10-K for 2025, filed February 2026; AbbVie neuroscience website page, October 2026; Juvmo product website, October 2026; Cerevel Therapeutics press release, April 18, 2024 (TEMPO-3 topline results); Cerevel Therapeutics Form 10-K for 2023, filed February 2024
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Number affected: Cerevel Therapeutics press release, April 2024

“As of 2022, nearly 1 million individuals in the U.S. are estimated to be affected by Parkinson’s disease, which is expected to increase to over 1.6 million by 2037.” (opens the source at this quote in a new tab)

Cited source: 2.1 Yang 2020; 2.2 Parkinson's Foundation 2026

Cerevel Therapeutics (2024) press release, April 18, 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

Number affected: AbbVie press release, September 2026

“More than 11 million people worldwide are living with Parkinson's disease,” (opens the source at this quote in a new tab)

Cited source: 2.3 Luo 2025

AbbVie (2026) press release, September 28, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: AbbVie press release, September 2025

“More than 11 million people worldwide are living with Parkinson's disease,” (opens the source at this quote in a new tab)

Cited source: 2.2 Parkinson's Foundation 2026

AbbVie (2025) press release, September 26, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Other countries and regions

No evidence found.

Geography not stated

No evidence found.

Sources the company cites

Yang 2020

Reference as the company lists it

“Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., & Thompson, T. (2020). Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinson's disease, 6, 15.” (opens the source at this quote in a new tab)

Cerevel Therapeutics (2024) press release, April 18, 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the nearest figure

“We estimated that 1.04 million individuals in the U.S. have been diagnosed with PD in 2017, with about 919,000 (89%) eligible for Medicare (91% age ≥65; 9% <65).” (opens the source at this quote in a new tab)

“Projected PD prevalence will be more than 1.6 million with projected total economic burden surpassing $79 billion by 2037.” (opens the source at this quote in a new tab)

Yang 2020, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Parkinson's foundation 2026

Reference as the company lists it, Cerevel Therapeutics press release, April 18, 2024

“Who has Parkinson's? Parkinson’s Foundation. Accessed October 20, 2023.” (opens the source at this quote in a new tab)

Cerevel Therapeutics (2024) press release, April 18, 2024, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Reference as the company lists it, AbbVie press release, September 26, 2025

“Statistics. Parkinson's Foundation. Available at:” (opens the source at this quote in a new tab)

AbbVie (2025) press release, September 26, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the nearest figure

“An estimated 1.1 million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030.” (opens the source at this quote in a new tab)

“More than 10 million people worldwide are estimated to be living with PD.” (opens the source at this quote in a new tab)

Parkinson's Foundation (2026) statistics page, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Luo 2025

Reference as the company lists it

“Luo Y, et al. Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021.” (opens the source at this quote in a new tab)

AbbVie (2026) press release, September 28, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“In 2021, 11.77 million people worldwide had Parkinson’s disease.” (opens the source at this quote in a new tab)

Luo 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

References

  1. AbbVie (2025) press release, September 26, 2025 (opens in a new tab)
  2. AbbVie (2026) press release, September 28, 2026 (opens in a new tab)
  3. Cerevel Therapeutics (2024) press release, April 18, 2024 (opens in a new tab)
  4. Luo 2025 (opens in a new tab)
  5. Parkinson's Foundation (2026) statistics page (opens in a new tab)
  6. Yang 2020 (opens in a new tab)